AWS
XFOR icon

Atria Wealth Solutions’s X4 Pharmaceuticals XFOR Stock Holding History

Atria Wealth Solutions’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,000
Closed -$44K – 2100
2024
Q4 		$44K Buy
+2,000
New +$31.9K ﹤0.01% 1942

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Atria Wealth Solutions's XFOR Position: Q1 2025 in Review

Atria Wealth Solutions sold out of X4 Pharmaceuticals (XFOR) in Q1 2025, closing a stake of 2,000 shares — an estimated $44K sold.

Atria Wealth Solutions first reported a position in XFOR in Q4 2024 and held it in 1 quarter. The position peaked at $44K in Q4 2024. 93 funds tracked by Wall St. Rank hold XFOR as of Q1 2025.

  • Atria Wealth Solutions reported no remaining X4 Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Atria Wealth Solutions sold 2,000 X4 Pharmaceuticals shares in Q1 2025, an estimated $44K.
  • Atria Wealth Solutions first reported a position in X4 Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Atria Wealth Solutions's X4 Pharmaceuticals position peaked at $44K in Q4 2024.
  • 93 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2025.

Based on Atria Wealth Solutions's 13F filing for Q1 2025, filed 9 May 2025.